Inventor · disambiguated record
Kristoffer Hellstrand
Also filed as: HELLSTRAND KRISTOFFER
16 granted patents·16 pending applications·137 citations·filing 1993–2020
94Inventor score
Files withMAXIM PHARM INC15HELLSTRAND KRISTOFFER3Immune pharmaceuticals inc2IMMUNE PHARMACEUTICALS LTD1MARTNER ANNA1
Top patents by PatentIndex Score
32 records- 0183US6407133B2Treatment and prevention of reactive oxygen metabolite-mediated cellular damageMAXIM PHARM INC·Filed 2001·Granted Jun 18, 2002·12 cites·7 claims
- 0281US6242473B1Treatment and prevention of reactive oxygen metabolite-mediated cellular damageMAXIM PHARM INC·Filed 1999·Granted Jun 5, 2001·33 cites·12 claims
- 0378US6893633B2Methods and compositions for promoting the maturation of monocytesMAXIM PHARM INC·Filed 2002·Granted May 17, 2005·8 cites·15 claims
- 0477US6790440B2Methods and compositions for promoting the maturation of monocytesMAXIM PHARM INC·Filed 2002·Granted Sep 14, 2004·7 cites·9 claims
- 0577US6305380B1Method for treatment of cancer and infectious diseaseMAXIM PHARM INC·Filed 2000·Granted Oct 23, 2001·8 cites·18 claims
- 0674US6730692B2Treatment and prevention of reactive oxygen metabolite-mediated cellular damageMAXIM PHARM INC·Filed 2002·Granted May 4, 2004·4 cites·13 claims
- 0772US6462067B1Treatment and prevention of reactive oxygen metabolite-mediated cellular damageMAXIM PHARM INC·Filed 2000·Granted Oct 8, 2002·3 cites·18 claims
- 0871US6613788B1Elevation of circulating blood histamine levelsMAXIM PHARM INC·Filed 2000·Granted Sep 2, 2003·2 cites·22 claims
- 0970US6821510B2Methods and compositions for promoting the maturation of monocytesMAXIM PHARM INC·Filed 2002·Granted Nov 23, 2004·3 cites·10 claims
- 1060US5728378APreparation for activation of natural killer cells (NK-cells), said preparation containing interferon-alpha and histamine, serotonin, amines or substances with corresponding receptor activityMAXIM PHARM INC·Filed 1993·Granted Mar 17, 1998·23 cites·15 claims
- 1158US2004191239A1Treatment and prevention of reactive oxygen metabolite-mediated cellular damageFiled 2004·Application pending·0 cites
- 1255US2023241029A1Methods of reducing post-surgical metastasisHELLSTRAND KRISTOFFER·Filed 2019·Application pending·0 cites
- 1355US2004219153A1Synergistic tumorcidal response induced by histamineFiled 2004·Application pending·0 cites
- 1454US6071942AElevation of circulating blood histamine levelsMAXIM PHARM INC·Filed 1997·Granted Jun 6, 2000·9 cites·9 claims
- 1554US2020399642A1Methods and compositions for treating and preventing metastatic tumorsImmune pharmaceuticals inc·Filed 2020·Application pending·0 cites
- 1654US2003017145A1Treatment and prevention of reactive oxygen metabolite-mediated cellular damageFiled 2002·Application pending·0 cites
- 1752US6498181B1Synergistic tumorcidal response induced by histamineMAXIM PHARMACEUTICALS·Filed 1999·Granted Dec 24, 2002·8 cites·1 claims
- 1851US2002094323A1Methods and compositions for promoting the maturation of monocytesFiled 2001·Application pending·0 cites
- 1951US2002193416A1Synergistic tumorcidal response induced by histamineFiled 2002·Application pending·0 cites
- 2050US2003149090A1Compositions for the treatment of infectious diseasesFiled 2002·Application pending·0 cites
- 2149US2021187072A1Methods and compositions for reducing risk of relapse and prolonging survival in acute myeloid leukemiaMARTNER ANNA·Filed 2019·Application pending·0 cites
- 2249US2002035998A1Method for treatment of cancer and infectious diseaseFiled 2001·Application pending·0 cites
- 2346US5961969AStable circulating histamine levelsMAXIM PHARM INC·Filed 1996·Granted Oct 5, 1999·8 cites·37 claims
- 2446US2020222505A1Methods of delaying and preventing acute myeloid leukemia relapseImmune pharmaceuticals inc·Filed 2018·Application pending·0 cites
- 2545US2004120926A1Reactive oxygen metabolite inhibitors for use in compositions and methods of treatmentFiled 2003·Application pending·0 cites
- 2645US2021292417A1Histamine dihydrochloride combinations and uses thereofIMMUNE PHARMACEUTICALS LTD·Filed 2017·Application pending·0 cites
- 2743US6155266AMethod for treatment of cancer and infectious diseaseMAXIM PHARM INC·Filed 1999·Granted Dec 5, 2000·3 cites·9 claims
- 2842US2003039628A1Activation and protection of T-cells (CD4+ and CD8+) using an H2 receptor agonist and other T-cell activating agentsFiled 2002·Application pending·0 cites
- 2942US2006079510A1Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosisHELLSTRAND KRISTOFFER·Filed 2005·Application pending·0 cites
- 3041US6221893B1Administration of histamine for therapeutic purposesMAXIM PHARM INC·Filed 1996·Granted Apr 24, 2001·5 cites·23 claims
- 3135US2012039844A1Composition and use of n-alpha-methylhistamine dihydrochloride for the reduction of oxygen radical formationHELLSTRAND KRISTOFFER·Filed 2010·Application pending·0 cites
- 3233US6003516AMethod for treatment of cancer and infectious diseaseMAXIM PHARM INC·Filed 1998·Granted Dec 21, 1999·1 cites·7 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →